MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 Visualizações
• 07/09/23
0
0
Embutir
administrator
Assinantes
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários